Bryce Point Capital LLC Invests $451,000 in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Bryce Point Capital LLC bought a new stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The fund bought 10,719 shares of the biopharmaceutical company's stock, valued at approximately $451,000.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in RARE. Franklin Resources Inc. lifted its holdings in shares of Ultragenyx Pharmaceutical by 95.2% during the fourth quarter. Franklin Resources Inc. now owns 427,359 shares of the biopharmaceutical company's stock valued at $17,979,000 after acquiring an additional 208,456 shares during the period. Alliancebernstein L.P. increased its position in shares of Ultragenyx Pharmaceutical by 5.3% during the 4th quarter. Alliancebernstein L.P. now owns 1,627,932 shares of the biopharmaceutical company's stock worth $68,487,000 after purchasing an additional 81,667 shares in the last quarter. California Public Employees Retirement System boosted its position in Ultragenyx Pharmaceutical by 15.1% in the fourth quarter. California Public Employees Retirement System now owns 131,344 shares of the biopharmaceutical company's stock valued at $5,526,000 after buying an additional 17,225 shares in the last quarter. Schroder Investment Management Group grew its stake in Ultragenyx Pharmaceutical by 105.7% during the fourth quarter. Schroder Investment Management Group now owns 376,161 shares of the biopharmaceutical company's stock worth $15,900,000 after buying an additional 193,296 shares during the last quarter. Finally, DnB Asset Management AS raised its stake in shares of Ultragenyx Pharmaceutical by 18.4% in the fourth quarter. DnB Asset Management AS now owns 12,132 shares of the biopharmaceutical company's stock valued at $510,000 after acquiring an additional 1,889 shares during the last quarter. Institutional investors own 97.67% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, EVP Karah Herdman Parschauer sold 2,990 shares of Ultragenyx Pharmaceutical stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $42.88, for a total value of $128,211.20. Following the sale, the executive vice president now owns 54,991 shares of the company's stock, valued at approximately $2,358,014.08. The trade was a 5.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Thomas Richard Kassberg sold 6,028 shares of the firm's stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $42.10, for a total transaction of $253,778.80. Following the sale, the executive vice president now owns 265,238 shares of the company's stock, valued at approximately $11,166,519.80. The trade was a 2.22 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 124,643 shares of company stock valued at $5,256,268 in the last 90 days. 5.80% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on RARE shares. HC Wainwright reiterated a "buy" rating and issued a $95.00 price target on shares of Ultragenyx Pharmaceutical in a report on Friday, February 14th. Wells Fargo & Company lifted their price target on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the stock an "overweight" rating in a research report on Friday, December 20th. Cantor Fitzgerald restated an "overweight" rating and issued a $118.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. Piper Sandler dropped their price objective on shares of Ultragenyx Pharmaceutical from $140.00 to $115.00 and set an "overweight" rating on the stock in a report on Monday, March 17th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $92.79.

Ultragenyx Pharmaceutical Price Performance

Shares of RARE traded down $2.16 during trading hours on Thursday, hitting $31.75. 265,839 shares of the stock were exchanged, compared to its average volume of 802,447. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $29.59 and a fifty-two week high of $60.37. The business has a 50-day moving average of $39.78 and a 200-day moving average of $45.21. The firm has a market capitalization of $2.98 billion, a P/E ratio of -5.00 and a beta of 0.61.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.32) by ($0.07). Ultragenyx Pharmaceutical had a negative net margin of 101.60% and a negative return on equity of 193.80%. The company had revenue of $164.88 million during the quarter, compared to the consensus estimate of $163.23 million. As a group, analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.